These data collectively demonstrate that TWF2 contributes to RCC cell migration, invasion, metastatic potential, and resistance to sunitinib, supporting its potential as a therapeutic target in drug‐resistant RCC. This evidence concerns the gene TWF2 and renal cell carcinoma.